Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.52 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.45 |
| ▸ | FDPS | P14324 | 8/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | CES1 | P23141 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetone SCHEMBL7095608 | 1.00 | CES2 (0.52) | CES2GGPS1FDPSEPHX1CES1 | |
| SCHEMBL28626290 | 0.95 | CES2 (0.52) | CES2GGPS1FDPSEPHX1CES1 | |
| SCHEMBL8595299 | 0.95 | CES2 (0.56) | CES2GGPS1FDPSEPHX1CES1 | |
| SCHEMBL6682242 | 0.95 | CES2 (0.56) | CES2GGPS1FDPSEPHX1CES1 | |
| Acetone SCHEMBL10601124 | 0.86 | CES2 (0.47) | CES2GGPS1FDPSEPHX1CES1 | |
| Acetone SCHEMBL5983365 | 0.86 | CES2 (0.47) | CES2GGPS1FDPSEPHX1CES1 | |
| SCHEMBL4361811 | 0.83 | CES2 (0.48) | CES2GGPS1FDPSEPHX1CES1 | |
| SCHEMBL7105885 | 0.83 | CES2 (0.48) | CES2GGPS1FDPSEPHX1CES1 | |
| SCHEMBL5027714 | 0.82 | CES2 (0.44) | CES2GGPS1FDPSEPHX1 | |
| Acetone SCHEMBL3269116 | 0.80 | FAAH (0.55) | CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1833477-B1 | PYRAZOLO-HETEROARYL COMPOUNDS USEFUL TO TREAT TNF-ALPHA AND IL-1 MEDIATED DISEASES | NOVARTIS AG (CH) | 2010-06-02 | — | — | EP | disclosed |
| EP-1833477-A1 | PYRAZOLO-HETEROARYL COMPOUNDS USEFUL TO TREAT TNF-ALPHA AND IL-1 MEDIATED DISEASES | Novartis AG (CH) | 2007-09-19 | — | — | EP | disclosed |
| US-20070196270-A1 | Compounds As Ccri Antagonists | HENG RICHARD | 2007-08-23 | — | — | US | disclosed |
| EP-1794164-A2 | BRIDGED PIPERAZINE AND PIPERIDINE DERIVATIVES AS CCR1 ANTAGONISTS | Novartis AG (CH) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006063820-A1 | PYRAZOLO-HETEROARYL COMPOUNDS USEFUL TO TREAT TNF-ALPHA AND IL-1 MEDIATED DISEASES | NOVARTIS AG (CH) | 2006-06-22 | — | — | WO | disclosed |
| EP-1150999-B1 | CYCLOSPORIN DERIVATIVES AND METHOD FOR THE PRODUCTION OF SAID DERIVATIVES | DEBIOPHARM SA (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005103054-A2 | BRIDGED PIPERAZINE AND PIPERIDINE DERIVATIVES AS CCRI ANTAGONISTS | NOVARTIS AG (CH) | 2005-11-03 | — | — | WO | disclosed |
| EP-0993456-B1 | 2-SUBSTITUTED 4,5-DIARYL IMIDAZOLES | NOVARTIS AG (CH) | 2004-09-08 | — | — | EP | disclosed |
| EP-1396491-A2 | 2-substituted 4,5-diaryl-imidazoles and their use as p38 MAP kinase inhibitors | Novartis AG (CH) | 2004-03-10 | — | — | EP | disclosed |
| EP-1150999-A1 | CYCLOSPORIN DERIVATIVES AND METHOD FOR THE PRODUCTION OF SAID DERIVATIVES | DEBIOPHARM S.A. (CH) | 2001-11-07 | — | — | EP | disclosed |
| US-6300347-B1 | FOR THERAPY OF TUMOR NECROSIS FACTOR AND INTERLEUKIN-1 MEDIATED DISEASES SUCH AS RHEUMATOID ARTHRITIS AND DISEASES OF BONE METABOLISM, E.G. OSTEOPOROSIS | NOVARTIS AG (CH) | 2001-10-09 | — | — | US | disclosed |
| WO-2000046239-A1 | CYCLOSPORIN DERIVATIVES AND METHOD FOR THE PRODUCTION OF SAID DERIVATIVES | DEBIOPHARM S.A. (CH) | 2000-08-10 | — | — | WO | disclosed |
| EP-0993456-A1 | 2-SUBSTITUTED 4,5-DIARYL IMIDAZOLES | Novartis AG (CH) | 2000-04-19 | — | — | EP | disclosed |
| WO-1999001449-A1 | 2-SUBSTITUTED 4,5-DIARYL IMIDAZOLES | NOVARTIS AG (CH) | 1999-01-14 | — | — | WO | disclosed |
| EP-0131500-B1 | RADIOPROTECTOR AGENTS WITH AN AMINOTHIOALKYL STRUCTURE, AND PROCESS FOR THEIR PREPARATION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1987-05-20 | — | — | EP | disclosed |
| WO-1985000167-A1 | NEW RADIOPROTECTOR AGENTS HAVING AN AMINO-THIOALKYL STRUCTURE AND PREPARATION METHOD THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 1985-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070196270-A1 | Compounds As Ccri Antagonists | CCR1, CCR10, CCR4 | CES2 493/4885GGPS1 3391/4885FDPS 3849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.